ClinicalTrials.gg
CompletedNCT01696032SGI-110Updated Aug 27, 2024Results posted

SGI-110 in Combination With Carboplatin in Ovarian Cancer

A Phase 2 interventional study of SGI-110 and Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) in Ovarian Cancer, sponsored by Astex Pharmaceuticals, Inc.. Completed at 24 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 166 studies testing carboplatin in Ovarian Neoplasms — 14 open to participants now, 21 under way, 6 of them phase 3. Carboplatin · Ovarian Neoplasms.

Enrollment
39th of 150
120 · median 48
Started
2012
with 3 others
Phase 2
84 of 166
8 open now
Registered
117th of 166
by date

Among the 166 studies testing carboplatin in Ovarian Neoplasms, this one is the 39th largest by enrollment of the 150 interventional ones that give a count, is one of 4 that started in 2012, is one of 84 in phase 2, and was the 117th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

14 of the 166 studies testing carboplatin in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies testing carboplatin in Ovarian Neoplasms, or all of them as a file.
02

Study summary

A 2-part, Phase 2 controlled, open-label, randomized study in participants with platinum-resistant recurrent ovarian cancer. In Part 1, participants received SGI-110 and carboplatin. The optimum dose of SGI-110 (guadecitabine) was identified in Part 1 based on safety and efficacy. In Part 2, participants were randomized to receive the dose identified in Part 1 plus carboplatin or one of four treatment of choice at the discretion of the investigator. The treatment of choice consisted of topotecan, pegylated liposomal doxorubicin, paclitaxel or gemcitabine.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Ovarian Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are women 18 years of age or older.
  2. Participants who have or cytologically confirmed recurrent high-grade serous epithelial ovarian cancer (Grade 2 or 3), primary peritoneal carcinomatosis or fallopian tube cancer.
  3. Participants who have platinum-resistant disease (defined as having within 6 months of her last platinum-containing regimen). There is no limit on the number of prior treatment regimens in Part 1. In Part 2, participants may have had no more than 3 prior cytotoxic treatment regimens, excluding or maintenance therapy.
  4. Participants must have had prior paclitaxel treatment.
  5. Participants who have according to v1.1 or detectable disease.
  6. Participants with performance status of 0 or 1.
  7. Participants with acceptable organ function.
  8. Participants must be at least 3 weeks from last chemotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have to SGI-110 and/or carboplatin or other components of these drug products.
  2. Participants who have received prior therapy with any hypomethylating agents.
  3. Participants who are to platinum treatment i.e., progressed while on platinum treatment.
  4. Participants with abnormal .
  5. Participants with Grade 2 or greater neuropathy.
  6. Participants with known .
  7. Participants with known history of , or .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    SGI-110 + Carboplatin

    Stage 1 was a safety lead-in stage with a dose escalation design. Participants were evaluated with the combination of SGI-110 (guadecitabine) plus carboplatin (G+C), given as 28-day treatment cycles: guadecitabine administered subcutaneous (SC) daily on Days 1-5, at a starting dose of 45 mg/m2/day in Cohort 1, followed by carboplatin intravenous (IV) based on a targeted dose of area under the curve (AUC) 5 on Day 8. After dose limiting toxicities were noted, guadecitabine dose was reduced to 30 mg/m2/day for subsequent cycles for 4 participants. Cohort 2 received 30 mg/m2/day guadecitabine and carboplatin IV AUC 4.

    Drug: SGI-110 · Drug: Carboplatin

  • Experimental
    SGI-110 + Carboplatin or TC

    Stage 2 was an open-label, randomized, controlled trial. Eligible participants were randomly assigned in a 1:1 ratio to receive either (1) G+C combination treatment in 28-day cycles at 30 mg/m2 SC once daily on Days 1-5 and carboplatin IV AUC 4 on Day 8, or (2) treatment of choice (TC) of topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel, or gemcitabine based on recommended dosing in 28-day cycles; participants initially randomized to TC were able to cross over to receive 30 mg/m2 G+C due to disease progression.

    Drug: SGI-110 · Drug: Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) · Drug: Carboplatin

Interventions

  • Also known as: guadecitabine

  • DrugTreatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)

    Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine

06

What researchers measure

Primary outcomes

  1. Stage 1: Dose Limiting Toxicities

    Number of participants with dose limiting toxicities (DLTs) in Stage 1

    Time frame: Up to 12 months

  2. Stage 2: Progression Free Survival

    Progression free survival (PFS) time was defined as the time interval from the date of the first dose of study medication until the earlier of disease progression or death. Participants were treated with their assigned treatment \[guadecitabine+carboplatin (G+C) or treatment choice (TC)\] until disease progression or unacceptable treatment-related toxicity occurred.

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective Response Rate

    The objective response rate (ORR) was defined as the proportion of participants who experienced an objective response (best overall response of complete response/full response or partial response, which was confirmed by a subsequent assessment at least 28 days later). Response categories were determined based on RECIST v1.1 criteria, or on modified Rustin (CA-125) criteria if response assessment could not be made using RECIST criteria.

    Time frame: Up to 24 months

  2. Progression Free Survival at 6 Months

    Progression free survival rate at 6 months is the proportion of participants who were alive and did not have disease progression at 6 months after start of treatment.

    Time frame: 6 months

  3. Clinical Benefit Rate

    Clinical benefit rate (CBR) was defined as the proportion of subjects who experienced a best overall response of complete response/full response or partial response (confirmed by a subsequent assessment at least 28 days later), or documented stable disease for at least 3 months after the first dose. Response categories were determined based on RECIST v1.1 criteria, then based on modified Rustin (CA-125) criteria if assessment could not be made using RECIST criteria.

    Time frame: Up to 24 months

  4. CA-125 Levels

    Percentage of participants with CA-125 reduction by ≥ 50% from baseline

    Time frame: Up to 24 months

  5. Duration of Response

    Duration of response is defined as the time between the date of the first documentation of complete response/full response or partial response, and the date of disease progression or date of death due to any cause, or the last adequate tumor assessment prior to the start of subsequent anti-cancer therapy including crossing over to G+C from TC arm, whichever occurred earlier. Only participants who responded were included in the duration of response calculation.

    Time frame: Up to 24 months

  6. Overall Survival

    Overall survival was defined as the number of days from the day the participant was administered the first dose of study treatment to the date of death (regardless of cause). Survival time was censored on the last date the participant was known to be alive or lost to follow-up before reaching the event of death; in the TC group, time was censored at the date of crossover.

    Time frame: Up to 24 months

  7. Stage 1: Pharmacokinetic Parameter Cmax

    Time to maximum plasma concentration for guadecitabine, decitabine and carboplatin

    Time frame: Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)

  8. Stage 1: Pharmacokinetic Parameter Tmax

    Time to last measurable concentration for guadecitabine, decitabine and carboplatin

    Time frame: Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)

  9. Stage 1: Pharmacokinetic Parameter AUC0-8

    Area under the concentration-time curve from 0 to 8 hours (AUC0-8) for guadecitabine, decitabine and carboplatin

    Time frame: Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)

07

Results

Posted May 25, 2021

Participant flow

A total of 124 participants were enrolled in the study and 120 were treated at 20 study centers, with 12 in the United States, 5 in the United Kingdom, and 3 in Canada. The enrollment period was 10 December 2012 (first participant dosed) to 12 May 2014 (last participant first dose).

Participant flow — Overall Study
MilestoneStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment Choice
Started1465149
Completed00027
Not completed1465122
Withdrew: Withdrawal by subject0012
Withdrew: Death1444318
Withdrew: Lost to follow-up0100
Withdrew: Database lock0172

Outcome measures

PrimaryStage 1: Dose Limiting Toxicities

Number of participants with dose limiting toxicities (DLTs) in Stage 1

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Stage 1: Dose Limiting Toxicities
ParticipantsStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2
Stage 1: Dose Limiting Toxicities04
PrimaryStage 2: Progression Free Survival

Progression free survival (PFS) time was defined as the time interval from the date of the first dose of study medication until the earlier of disease progression or death. Participants were treated with their assigned treatment \[guadecitabine+carboplatin (G+C) or treatment choice (TC)\] until disease progression or unacceptable treatment-related toxicity occurred.

Time frame:
Up to 24 months
Reported as:
Median · Days
Stage 2: Progression Free Survival
DaysStage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment Choice
Stage 2: Progression Free Survival114 (63 to 169)64 (52 to 105)
Statistical analysis
  • Stage 2: Guadecitabine+Carboplatin 30 mg/m2 vs Stage 2: Treatment Choice · Log Rank · p = 0.0654
SecondaryObjective Response Rate

The objective response rate (ORR) was defined as the proportion of participants who experienced an objective response (best overall response of complete response/full response or partial response, which was confirmed by a subsequent assessment at least 28 days later). Response categories were determined based on RECIST v1.1 criteria, or on modified Rustin (CA-125) criteria if response assessment could not be made using RECIST criteria.

Time frame:
Up to 24 months
Reported as:
Number · Percent
Objective Response Rate
PercentStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
Objective Response Rate21 (4.7 to 50.8)0 (0.0 to 45.9)16 (7.0 to 28.6)8 (2.3 to 19.6)4 (0.1 to 19.0)
SecondaryProgression Free Survival at 6 Months

Progression free survival rate at 6 months is the proportion of participants who were alive and did not have disease progression at 6 months after start of treatment.

Time frame:
6 months
Reported as:
Number · Percent of participants
Progression Free Survival at 6 Months
Percent of participantsStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
Progression Free Survival at 6 Months0.36 (0.13 to 0.59)0.33 (0.05 to 0.68)0.37 (0.24 to 0.50)0.11 (0.04 to 0.22)0.19 (0.07 to 0.35)
SecondaryClinical Benefit Rate

Clinical benefit rate (CBR) was defined as the proportion of subjects who experienced a best overall response of complete response/full response or partial response (confirmed by a subsequent assessment at least 28 days later), or documented stable disease for at least 3 months after the first dose. Response categories were determined based on RECIST v1.1 criteria, then based on modified Rustin (CA-125) criteria if assessment could not be made using RECIST criteria.

Time frame:
Up to 24 months
Reported as:
Number · Percent of participants
Clinical Benefit Rate
Percent of participantsStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
Clinical Benefit Rate43 (17.7 to 71.1)50 (11.8 to 88.2)41 (27.6 to 55.8)29 (16.6 to 43.3)19 (6.3 to 38.1)
SecondaryCA-125 Levels

Percentage of participants with CA-125 reduction by ≥ 50% from baseline

Time frame:
Up to 24 months
Reported as:
Number · Percent of participants
CA-125 Levels
Percent of participantsStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
CA-125 Levels27 (6.0 to 61.0)50 (6.8 to 93.2)36 (21.6 to 52.0)32 (18.1 to 48.1)29 (11.3 to 52.2)
SecondaryDuration of Response

Duration of response is defined as the time between the date of the first documentation of complete response/full response or partial response, and the date of disease progression or date of death due to any cause, or the last adequate tumor assessment prior to the start of subsequent anti-cancer therapy including crossing over to G+C from TC arm, whichever occurred earlier. Only participants who responded were included in the duration of response calculation.

Time frame:
Up to 24 months
Reported as:
Median · Days
Duration of Response
DaysStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
Duration of Response225 (42.0 to 294.0)195 (114.0 to NA)186 (147.0 to 241.0)173 (121.0 to 267.0)182 (147.0 to 233.0)
SecondaryOverall Survival

Overall survival was defined as the number of days from the day the participant was administered the first dose of study treatment to the date of death (regardless of cause). Survival time was censored on the last date the participant was known to be alive or lost to follow-up before reaching the event of death; in the TC group, time was censored at the date of crossover.

Time frame:
Up to 24 months
Reported as:
Median · Days
Overall Survival
DaysStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
Overall Survival341 (100.0 to 567.0)195 (25.0 to NA)331 (231 to 415)221 (145 to 372)279 (161.0 to 413.0)
SecondaryStage 1: Pharmacokinetic Parameter Cmax

Time to maximum plasma concentration for guadecitabine, decitabine and carboplatin

Time frame:
Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)
Reported as:
Mean · ng/mL
Stage 1: Pharmacokinetic Parameter Cmax
ng/mLStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2
Guadecitabine96.2 ± 78.3109 ± 70.8
Decitabine22.6 ± 13.326.3 ± 14.5
Carboplatin19600 ± 565021900 ± 13800
SecondaryStage 1: Pharmacokinetic Parameter Tmax

Time to last measurable concentration for guadecitabine, decitabine and carboplatin

Time frame:
Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)
Reported as:
Median · Hours
Stage 1: Pharmacokinetic Parameter Tmax
HoursStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2
Guadecitabine1.42 (0.25 to 6.00)1.98 (1.50 to 7.25)
Decitabine1.98 (1.00 to 6.00)3.95 (1.67 to 7.25)
Carboplatin1.03 (0.48 to 1.20)1.05 (0.48 to 1.20)
SecondaryStage 1: Pharmacokinetic Parameter AUC0-8

Area under the concentration-time curve from 0 to 8 hours (AUC0-8) for guadecitabine, decitabine and carboplatin

Time frame:
Pre-dose and up to 8 hours post-dose on Cycle 1 Day 1 for guadecitabine and decitabine and Day 8 for carboplatin (28 day cycles)
Reported as:
Mean · Hours*ng/mL
Stage 1: Pharmacokinetic Parameter AUC0-8
Hours*ng/mLStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2
Guadecitabine239 ± 136416 ± 217
Decitabine71.1 ± 26.6129 ± 17.9
Carboplatin51200 ± 1210041900 ± 31700

Adverse events

Collected over Approximately 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1: Guadecitabine+Carboplatin 30 mg/m214/14 (100%)8/14 (57.1%)14/14 (100%)
Stage 1: Guadecitabine+Carboplatin 45 mg/m24/6 (66.7%)4/6 (66.7%)6/6 (100%)
Stage 2: Guadecitabine+Carboplatin 30 mg/m243/51 (84.3%)26/51 (51%)50/51 (98%)
Stage 2: Treatment Choice18/49 (36.7%)24/49 (49%)49/49 (100%)
Stage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m222/27 (81.5%)12/27 (44.4%)27/27 (100%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
NeutropeniaBlood and lymphatic system disorders1/142/61/510/491/27
VomitingGastrointestinal disorders2/142/61/515/492/27
NauseaGastrointestinal disorders2/142/60/512/491/27
Abdominal painGastrointestinal disorders0/140/62/513/495/27
Adverse drug reactionGeneral disorders0/141/60/510/490/27
Mental status changePsychiatric disorders0/141/60/511/490/27
AnemiaBlood and lymphatic system disorders0/141/61/511/490/27
ThrombocytopeniaBlood and lymphatic system disorders0/141/60/510/490/27
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/141/60/512/491/27
Cerebrovascular accidentNervous system disorders0/141/60/511/490/27
Most frequent other events
Showing 10 of 167
Most frequent other events
EventStage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceStage 2: Crossover Treatment Choice to Guadecitabine+Carboplatin 30 mg/m2
ThrombocytopeniaBlood and lymphatic system disorders3/146/612/5112/4910/27
NeutropeniaBlood and lymphatic system disorders7/145/636/5116/4918/27
NauseaGastrointestinal disorders10/142/638/5128/4912/27
FatigueGeneral disorders9/144/633/5126/4914/27
PyrexiaGeneral disorders2/144/68/513/493/27
AnemiaBlood and lymphatic system disorders7/144/616/5125/498/27
ConstipationGastrointestinal disorders5/144/622/5117/4910/27
HypomagnesemiaMetabolism and nutrition disorders3/144/615/518/499/27
VomitingGastrointestinal disorders6/142/632/5115/4910/27
Injection site reactionGeneral disorders8/142/623/511/499/27

Baseline characteristics

Includes all treated participants

Age, Continuous
Age, Continuous(Years)Stage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceTotal
Mean57.99 ± 9.4756.79 ± 13.2061.96 ± 9.1762.09 ± 9.6261.29 ± 9.62
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceTotal
Female1465149120
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceTotal
Hispanic or Latino10236
Not Hispanic or Latino1364946114
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stage 1: Guadecitabine+Carboplatin 30 mg/m2Stage 1: Guadecitabine+Carboplatin 45 mg/m2Stage 2: Guadecitabine+Carboplatin 30 mg/m2Stage 2: Treatment ChoiceTotal
American Indian or Alaska Native00000
Asian015511
Native Hawaiian or Other Pacific Islander00011
Black or African American10225
White1254340100
More than one race00000
Unknown or Not Reported10113
08

Study locations

24 sites
  • Norris Comprehensive Cancer Center- University of Southern California
    Los Angeles, California 90033, United States
  • University of Florida Shands Cancer Center
    Gainesville, Florida 32610, United States
  • Georgia Health Sciences University
    Augusta, Georgia 30912, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Melvin and Bren Simon Cancer Center- Indiana University
    Indianapolis, Indiana 46202, United States
  • Women's Cancer Care
    Covington, Louisiana 70433, United States
  • Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Island Gynecologic Oncology
    Brightwaters, New York 11718, United States
  • Duke Cancer Institute- Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati Cancer Institute
    Cincinnati, Ohio 45267, United States
  • Mary Crowley Medical Research Center
    Dallas, Texas 75201, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • CHUM Gynecologie-Oncologie, Notre Dame Hospital
    Montreal, Quebec H2L 4M1, Canada
  • Bristol Heamatology and Oncology Centre
    Bristol, BS2 8ED, United Kingdom
  • St. James Univesity Hospital - St. James Institute of Oncology
    Leeds, LS9 7TF, United Kingdom
  • Cambridge University Hospitals NHS Foundation and Trust
    London, EC1V 4AD, United Kingdom
  • Univesity College Hospital
    London, NW1 2PG, United Kingdom
  • Imperial College Health Care NHS Trust-Garry Weston Centre
    London, W12 0NN, United Kingdom
  • Mount Vernon Cancer Centre
    Middlesex, HA6 2RN, United Kingdom
  • Royal Marsden Foundation Trust
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Cardenas H, Fang F, Jiang G, Perkins SM, Zhang C, Emerson RE, Hutchins G, Keer HN, Liu Y, Matei D, Nephew K. Methylomic Signatures of High Grade Serous Ovarian Cancer. Epigenetics. 2021 Nov;16(11):1201-1216. doi: 10.1080/15592294.2020.1853402. Epub 2020 Dec 8. PubMed 33289590 ↗
  • Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 Mar 1;26(5):1009-1016. doi: 10.1158/1078-0432.CCR-19-1638. Epub 2019 Dec 12. PubMed 31831561 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 4 years 9 months after primary completion. A results delay was requested in Jan 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2012
First posted
Sep 28, 2012
Start
Sep 2012
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results delay requested
Jan 15, 2018
Results first posted
May 25, 2021
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01696032
Responsible party
Sponsor
First posted
Sep 28, 2012
Start date
Sep 2012
Primary completion
Aug 2016
Completion
Aug 2016
Results posted
May 25, 2021
Last update
Aug 27, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Guadecitabine · Carboplatin

Start the discussion